ASCO 2023 | THORA: high dose radiotherapy in SCLC

Bjorn Henning Gronberg, MD, PhD, Norwegian University of Science and Technology, Trondheim, Norway, explains the results of the THORA trial (NCT02041845), which aimed to compare high dose with standard dose thoracic radiotherapy in limited stage small cell lung cancer (SCLC). Data previously presented showed that there were improvements for the primary end point of two-year survival in patients who received higher doses of radiotherapy. Additionally, median overall survival (OS) and five-year survival rates also mirror this trend. Higher doses of radiotherapy did not correlate with higher rates of toxicity. The survival difference observed is clinically relevant and has become the standard treatment schedule in Norway. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.